Increase in FeNO Levels Following IL5/IL5R-Targeting Therapies in Severe Asthma: A Case Series

References

• FitzGerald JMLC, Lougheed MD, Lougheed MD, et al. Recognition and management of severe asthma, A Canadian Thoracic Society position statement. Can J Respir Crit Care Sleep Med. 2017;1(4):199–221. doi:10.1080/24745332.2017.1395250
   Web of Science ®Google Scholar
• Shaw DE, Sousa AR, Fowler SJ, et al. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. Eur Respir J. 2015;46(5):1308–1321. doi:10.1183/13993003.00779-2015
   PubMed Web of Science ®Google Scholar
• Global initiative for asthma. Difficult-to-treat & Severe asthma in adolescent and adult patients - diagnosis and management. Available from: www.ginasthma.org. Accessed May 5, 2022.
   Google Scholar
• Schleich FN, Chevremont A, Paulus V, et al. Importance of concomitant local and systemic eosinophilia in uncontrolled asthma. Eur Respir J. 2014;44(1):97–108. doi:10.1183/09031936.00201813
   PubMed Web of Science ®Google Scholar
• Coverstone AM, Seibold MA, Peters MC. Diagnosis and management of T2-high asthma. J Allergy Clin Immunol Pract. 2020;8(2):442–450. doi:10.1016/j.jaip.2019.11.020
   PubMed Web of Science ®Google Scholar
• Donohue JF, Jain N. Exhaled nitric oxide to predict corticosteroid responsiveness and reduce asthma exacerbation rates. Respir Med. 2013;107(7):943–952. doi:10.1016/j.rmed.2013.02.018
   PubMed Web of Science ®Google Scholar
• Szefler SJ, Wenzel S, Brown R, et al. Asthma outcomes, biomarkers. J Allergy Clin Immunol. 2012;129(3Suppl):S9–23. doi:10.1016/j.jaci.2011.12.979
   PubMed Web of Science ®Google Scholar
• Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM), a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651–659. doi:10.1016/s0140-6736(12)60988-x
   PubMed Web of Science ®Google Scholar
• Castro M, Wenzel SE, Bleecker ER, et al. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma, a phase 2b randomised dose-ranging study. Lancet Respir Med. 2014;2(11):879–890. doi:10.1016/s2213-2600(14)70201-2
   PubMed Web of Science ®Google Scholar
• Hsu C, Diaz J. M201 should FENO be used as a biomarker to measure response to benralizumab? Ann Allergy Asthma Immunol. 2019;123(5):S99. doi:10.1016/j.anai.2019.08.188
   Web of Science ®Google Scholar
• Dweik RA, Boggs PB, Erzurum SC, et al. An official ATS clinical practice guideline, interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011;184(5):602–615. doi:10.1164/rccm.9120-11ST
   PubMed Web of Science ®Google Scholar
• Jeppegaard M, Veidal S, Sverrild A, Backer V, Porsbjerg C. Validation of ATS clinical practice guideline cut-points for FeNO in asthma. Respir Med. 2018;144:22–29. doi:10.1016/j.rmed.2018.09.014
   PubMed Web of Science ®Google Scholar
• Liu J, Xu R, Zhan C, et al. Clinical utility of ultrahigh fractional exhaled nitric oxide in predicting bronchial hyperresponsiveness in patients with suspected asthma. Postgrad Med J. 2019;95(1128):541–546. doi:10.1136/postgradmedj-2018-136333
   PubMed Web of Science ®Google Scholar
• Guo FH, De Raeve HR, Rice TW, Stuehr DJ, Thunnissen FB, Erzurum SC. Continuous nitric oxide synthesis by inducible nitric oxide synthase in normal human airway epithelium in vivo. Proc Natl Acad Sci U S A. 1995;92(17):7809–7813. doi:10.1073/pnas.92.17.7809
   PubMed Web of Science ®Google Scholar
• Duong-Quy S. Clinical utility of the exhaled Nitric Oxide (NO) measurement with portable devices in the management of allergic airway inflammation and asthma. J Asthma Allergy. 2019;12:331–341. doi:10.2147/jaa.S190489
   PubMed Web of Science ®Google Scholar
• Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475–2485. doi:10.1056/NEJMoa1804093
   PubMed Web of Science ®Google Scholar
• Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486–2496. doi:10.1056/NEJMoa1804092
   PubMed Web of Science ®Google Scholar
• Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368(26):2455–2466. doi:10.1056/NEJMoa1304048
   PubMed Web of Science ®Google Scholar
• Izumo T, Tone M, Kuse N, et al. Effectiveness and safety of benralizumab for severe asthma in clinical practice (J-BEST), a prospective study. Ann Transl Med. 2020;8(7):438. doi:10.21037/atm.2020.04.01
   PubMed Web of Science ®Google Scholar
• Ramonell RP, Lee FE, Levy JM, Kuruvilla M. Exhaled nitric oxide measurements are not influenced by anti-eosinophil therapy in patients with asthma, A retrospective analysis. Ann Allergy Asthma Immunol. 2021;126(1):102–104. doi:10.1016/j.anai.2020.09.005
   PubMed Web of Science ®Google Scholar
• Crimi C, Campisi R, Nolasco S, et al. Mepolizumab effectiveness in patients with severe eosinophilic asthma and co-presence of bronchiectasis, A real-world retrospective pilot study. Respir Med. 2021;185:106491. doi:10.1016/j.rmed.2021.106491
   PubMed Web of Science ®Google Scholar
• Pelaia C, Crimi C, Benfante A, et al. Therapeutic effects of benralizumab assessed in patients with severe eosinophilic asthma, real-life evaluation correlated with allergic and non-allergic phenotype expression. J Asthma Allergy. 2021;14:163–173. doi:10.2147/jaa.S297273
   PubMed Web of Science ®Google Scholar
• Gratziou C, Lignos M, Dassiou M, Roussos C. Influence of atopy on exhaled nitric oxide in patients with stable asthma and rhinitis. Eur Respir J. 1999;14(4):897–901. doi:10.1034/j.1399-3003.1999.14d28.x
   PubMed Web of Science ®Google Scholar
• Galli J, Montuschi P, Passàli GC, Laruffa M, Parrilla C, Paludetti G. Exhaled nitric oxide measurement in patients affected by nasal polyposis. Otolaryngol Head Neck Surg. 2012;147(2):351–356. doi:10.1177/0194599812442322
   PubMed Web of Science ®Google Scholar
• Watkins DN, Lewis RH, Basclain KA, et al. Expression and localization of the inducible isoform of nitric oxide synthase in nasal polyp epithelium. Clin Exp Allergy. 1998;28(2):211–219. doi:10.1046/j.1365-2222.1998.00215.x
   PubMed Web of Science ®Google Scholar
• Maniscalco M, Calabrese C, D’Amato M, et al. Association between exhaled nitric oxide and nasal polyposis in severe asthma. Respir Med. 2019;152:20–24. doi:10.1016/j.rmed.2019.04.017
   PubMed Web of Science ®Google Scholar
• Clearie KL, McKinlay L, Williamson PA, Lipworth BJ. Fluticasone/Salmeterol combination confers benefits in people with asthma who smoke. Chest. 2012;141(2):330–338. doi:10.1378/chest.11-0392
   PubMed Web of Science ®Google Scholar
• Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β(2)-agonists (SIROCCO), a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115–2127. doi:10.1016/s0140-6736(16)31324-1
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA), a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128–2141. doi:10.1016/s0140-6736(16)31322-8
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207. doi:10.1056/NEJMoa1403290
   PubMed Web of Science ®Google Scholar
• Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360(10):973–984. doi:10.1056/NEJMoa0808991
   PubMed Web of Science ®Google Scholar
• Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376(25):2448–2458. doi:10.1056/NEJMoa1703501
   PubMed Web of Science ®Google Scholar
• Flood-Page P, Swenson C, Faiferman I, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med. 2007;176(11):1062–1071. doi:10.1164/rccm.200701-085OC
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. PRODUCT MONOGRAPH – NUCALA. Updated Nov 5; 2021. Available from: https://ca.gsk.com/media/6195/nucala-pm-en.pdf. Accessed May 5, 2022.
   Google Scholar
• AstraZeneca. Product Monograph – Fasenra. Updated August 20; 2021. Available from: https://www.astrazeneca.ca/content/dam/az-ca/downloads/productinformation/fasenra-product%20monograph-en.pdf. Accessed May 5, 2022.
   Google Scholar
• Moran AM, Ramakrishnan S, Borg CA, et al. Blood eosinophil depletion with mepolizumab, benralizumab, and prednisolone in eosinophilic asthma. Am J Respir Crit Care Med. 2020;202(9):1314–1316. doi:10.1164/rccm.202003-0729LE
   PubMed Web of Science ®Google Scholar